[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-380584-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-380584-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","current-application-of-nanoparticle-drug-delivery-systems-to-the-treatment-of-anaplastic-thyroid-carcinomas-review","Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas - review","","Anaplastic thyroid carcinomas (ATCs) are rare but highly invasive and often fatal, making treatment especially difficult. Clinical management typically favors a comprehensive individualized approach combining surgery, radiotherapy, chemotherapy, BRAF/MEK inhibitors, and immunotherapy, with surgery-based strategies potentially benefiting stage IVA/IVB patients. Patients with stage IVC show limited benefit from current therapies. Nanoparticle delivery of siRNAs, targeted and cytotoxic drugs, photosensitizers, and other agents is emerging as a promising anti-cancer strategy. This review summarizes recent advances in nanoparticle drug delivery for ATC to support further study.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/current-application-of-nanoparticle-drug-delivery-systems-to-the-treatment-of-anaplastic-thyroid-carcinomas-review/380584/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/current-application-of-nanoparticle-drug-delivery-systems-to-the-treatment-of-anaplastic-thyroid-carcinomas-review/380584.png","ImageObject",300,407,{"name":42,"@type":43},"Mimi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are anaplastic thyroid carcinomas considered difficult to treat?","Question",{"text":63,"@type":64},"ATCs are rare but highly invasive and fatal, with rapid onset and poor prognosis. Median survival is less than 5 months, and most patients show local infiltration and distant metastases at diagnosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatment strategy is currently preferred for ATC patients?",{"text":68,"@type":64},"A comprehensive individualized plan is preferred, typically combining surgery, radiotherapy, chemotherapy, BRAF/MEK inhibitors, and immunotherapy. Surgery-based comprehensive treatment may provide survival benefits for stage IVA/IVB patients.",{"name":70,"@type":61,"acceptedAnswer":71},"How do nanoparticle drug delivery systems contribute to ATC treatment research?",{"text":72,"@type":64},"Nanoparticle delivery is explored as a promising anti-cancer approach, including delivery of siRNAs, targeted drugs, cytotoxic agents, and photosensitizers. The review highlights growing interest in hybrid nanoparticles as carriers for multiple therapeutic modalities in ATC.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},380584,1790708833,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","International Journal of Nanomedicine Dovepress  \nopen access to scientific and medical research  \n Open Access Full Text Article REVIEW  \nCurrent Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas  \nChonggao Wang 1 , 2 , Yewei Zhang 3  \n1Department of Thyroid Surgery, Nanjing Hospital of Chinese Medicine, Nanjing, 210001, People’s Republic of China; 2School of Medicine, Southeast University, Nanjing, 210001, People’s Republic of China; 3Hepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210009, People’s Republic of China  \nCorrespondence: Yewei Zhang, Email [zhangyewei@njmu.edu.cn](zhangyewei@njmu.edu.cn)  \n\n| Abstract: Anaplastic thyroid carcinomas (ATCs) are a rare subtype of thyroid cancers with a low incidence but extremely high invasiveness and fatality. The treatment of ATCs is very challenging, and currently, a comprehensive individualized therapeutic strategy involving surgery, radiotherapy (RT), chemotherapy, BRAF/MEK inhibitors (BRAFi/MEKi) and immunotherapy is preferred. For ATC patients in stage IVA/IVB, a surgery-based comprehensive strategy may provide survival benefits. Unfortunately, ATC patients in IVC stage barely get benefits from the current treatment. Recently, nanoparticle delivery of siRNAs, targeted drugs, cytotoxic drugs, photosensitizers and other agents is considered as a promising anti-cancer treatment. Nanoparticle drug delivery systems have been mainly explored in the treatment of differentiated thyroid cancer (DTC) . With the rapid development of drug delivery techniques and nanomaterials, using hybrid nanoparticles as the drug carrier to deliver siRNAs, targeted drugs, immune drugs, chemotherapy drugs and phototherapy drugs to ATC patients have become a hot research field. This review aims to describe latest findings of nanoparticle drug delivery systems in the treatment of ATCs, thus providing references for the further analyses. Keywords: anaplastic thyroid carcinomas, anti-cancer treatment, nanomaterials, nanoparticle, nanomedicine |\n| --- |\n| Introduction\u003Cbr>Anaplastic thyroid carcinomas (ATCs) are a type of rare malignancy with an annual incidence of 0.12/100,000 and 0.1–0.3/\u003Cbr>100,000 in the United States1 and Europe,2,3 respectively. It is characterized by rapid onset and poor prognosis. The median survival of ATC patients is less than 5 months, with the 2-year and 5-year survival of less than 15% and 7%, respectively.4 Local infiltration of the trachea, esophagus, blood vessels, and muscles, and distant metastases of the lung, pleura, bone, and brain are detectable in most of ATC patients at the initial time of diagnosis, which are all surgical contraindications5 (Figures 1 and 2). Notably, about 5–20% of DTC patients can experience dedifferentiation and aggravate into ATCs.6\u003Cbr>Generally speaking, surgery-based comprehensive treatment provides survival benefits to ATC patients in stage IVA with the tumor lesions restricted within the thyroid. However, the application of surgery to ATC patients in stage IVB/ IVC with extra thyroid metastases is controversial. Xu et al7 reported that the scope of surgery and the integrity of tumor resection do not influence the survival of ATC. The majority of ATC patients can only be treated with local RT, systemic chemotherapy, targeted therapy and immunotherapy8,9 (Figure 3) .\u003Cbr>External beam radiation therapy (EBRT) is still preferred to ATC patients in R0/R1 resection. A retrospective study illustrated that EBRT is highly heterogenic in dose management, division, technique and combination treatment.10 The clinical benefit of EBRT on the prognosis relies on the combination with surgery and chemotherapy. Chemotherapy is a widely recognized treatment to prolong the survival.11 The latest American Thyroid Association guidelines recommended the systemic treatment of ATC using genotoxic drugs like paclitaxel plus carboplatin, cisplatin plus doxorubicin, d","cbCaiujynrDqDlLo","https://ap.wps.com/l/cbCaiujynrDqDlLo","pdf",4007657,22,"English","# Introduction\n## Multimodal therapy challenges in ATC\n## Treatment options across stages\n# Nanoparticle drug delivery in ATC\n## Rationale and therapeutic agents","[{\"question\":\"Why are anaplastic thyroid carcinomas considered difficult to treat?\",\"answer\":\"ATCs are rare but highly invasive and fatal, with rapid onset and poor prognosis. Median survival is less than 5 months, and most patients show local infiltration and distant metastases at diagnosis.\"},{\"question\":\"What treatment strategy is currently preferred for ATC patients?\",\"answer\":\"A comprehensive individualized plan is preferred, typically combining surgery, radiotherapy, chemotherapy, BRAF/MEK inhibitors, and immunotherapy. Surgery-based comprehensive treatment may provide survival benefits for stage IVA/IVB patients.\"},{\"question\":\"How do nanoparticle drug delivery systems contribute to ATC treatment research?\",\"answer\":\"Nanoparticle delivery is explored as a promising anti-cancer approach, including delivery of siRNAs, targeted drugs, cytotoxic agents, and photosensitizers. The review highlights growing interest in hybrid nanoparticles as carriers for multiple therapeutic modalities in ATC.\"}]","Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas - review | PDF",1790240758,55]